Codexis
Codexis is redefining what is possible in therapeutic development and manufacturing, leading the technology revolution with efficient, high-quality, and commercially proven solutions. The company’s manufacturing platforms consistently outperform legacy methods, enabling the development of therapeutic possibilities that were previously out of reach. With a proven track record, proprietary …
Profile
- Industry
- Industrial chemistry
- Topics
- Enzymes & biocatalysis
- Role
- Producer — “…proteins for pharmaceutical manufacturing and diagnostic applications. Founded in 2002, the company utilizes i…”
- Why it is bioeconomy
- Codexis is a biotechnology company that engineers enzymes for pharmaceutical biocatalysis and RNA manufacturing applications.
Bio-solutions it supplies 0
Not yet cited as a supplier in a graded solution.
What they offer
This company does not publish its products or services — we find out through an introduction.
Status
Recent news 5
Found by automated search; summaries are machine-written in English. The headline names the company or the summary is about it — check the source before relying on it.
- 2026-09-28 Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA :: … ir.codexis.comCodexis announces a collaboration with a leading siRNA drug innovator to use its ECO Synthesis platform for enzymatic, stereo-defined fragment synthesis and ligation into final siRNA duplexes, comparing with solid-phase methods to assess purity and quality. This underscores …
- 2026-08-12 Codexis Reports Second Quarter 2026 Financial Results - BioSpace biospace.comCodexis reported Q2 2026 revenue of $14.9 million, reiterated full-year guidance (revenues $72–$76 million; gross margin high‑60s%), and healthy cash runway (pro forma ~$80 million after a July $25 million equity raise). The company highlighted progress commercialization of its …
- 2026-08-03 Codexis Appoints David Butler, PhD, to Strategic Advisory globenewswire.comCodexis is expanding its strategic leadership by adding David Butler, PhD, to its Strategic Advisory Board, signaling a focus on advancing siRNA therapeutics and industrializing its enzymatic technology for scalable manufacturing. The company also acknowledges Carole Cobb’s …
- 2026-08-03 Codexis Appoints David Butler, PhD, to Strategic Advisory globenewswire.comCodexis is expanding its strategic leadership by adding David Butler, PhD, to its Strategic Advisory Board to bolster its growth and expertise in siRNA therapeutics and scalable enzymatic manufacturing, while thanking Carole Cobb for her contributions as she steps down. The …
- 2026-07-24 Codexis Prices $23.1M Public Offering | GenomeWeb genomeweb.comCodexis is raising about $23.1 million from a public stock offering at $1.50 per share (approximately 16.7 million shares with an option for up to 2.5 million more), to fund working capital, R&D, and general corporate purposes; the company also reports solid Q1 revenue growth …
Network: owners, partners, peers
Similar companies
Genencor · Amyris · EDT-Enzymatic Deinking Technologies, LLC · Jeneil Biotech, Inc. · Dyadic Applied BioSolutions · Yzymes · Protein Evolution · Mascoma LLC
Company facts
Registry identifiers
- I.R.S. Employer Identification No.: 71-0872999
Funding
- Latest round: Post ipo equity · 2026-07-01
- Total raised: US$ 229.3 M
From automated research (company websites, filings, a commercial company index); not checked by hand. Registry identifiers: confirm in the official registry.
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member